c-MET (Y1230C)

MET · Variant type: point · HGVS: p.Y1230C

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Cabozantinib	98.7%	1.3%	92.73
2	Crizotinib	92.9%	7.1%	91.39
3	Gilteritinib	88.4%	11.6%	88.97
4	Tivozanib	77.6%	22.4%	92.42
5	Pacritinib	67.4%	32.6%	88.64
6	Defactinib	61.9%	38.1%	92.68
7	Afatinib	60.3%	39.7%	98.50
8	Lenvatinib	58.6%	41.4%	97.74
9	Repotrectinib	52.1%	47.9%	84.21
10	Vemurafenib	49.6%	50.4%	96.49
11	Canertinib	48.0%	52.0%	96.49
12	Neratinib	44.9%	55.1%	93.18
13	Fedratinib	41.6%	58.4%	96.21
14	Axitinib	40.5%	59.5%	93.23
15	Dacomitinib	39.0%	61.0%	97.99
16	Selpercatinib	38.4%	61.6%	96.72
17	Tepotinib	36.4%	63.6%	99.75
18	Fostamatinib	33.8%	66.2%	96.74
19	Sunitinib	31.9%	68.1%	91.73
20	Dabrafenib	31.3%	68.7%	94.74
21	Entrectinib	27.9%	72.1%	93.69
22	Pexidartinib	25.9%	74.1%	99.49
23	Capmatinib	25.3%	74.7%	99.75
24	Ponatinib	25.1%	74.9%	78.23
25	Abemaciclib	21.6%	78.4%	91.48

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Cabozantinib	98.7%	—	—
Crizotinib	92.9%	—	—
Gilteritinib	88.4%	—	—
Tivozanib	77.6%	—	—
Pacritinib	67.4%	—	—
Defactinib	61.9%	—	—
Afatinib	60.3%	—	—
Lenvatinib	58.6%	—	—
Repotrectinib	52.1%	—	—
Vemurafenib	49.6%	—	—
Canertinib	48.0%	—	—
Neratinib	44.9%	—	—
Fedratinib	41.6%	—	—
Axitinib	40.5%	—	—
Dacomitinib	39.0%	—	—
Selpercatinib	38.4%	—	—
Tepotinib	36.4%	—	—
Fostamatinib	33.8%	—	—
Sunitinib	31.9%	—	—
Dabrafenib	31.3%	—	—
Entrectinib	27.9%	—	—
Pexidartinib	25.9%	—	—
Capmatinib	25.3%	—	—
Ponatinib	25.1%	—	—
Abemaciclib	21.6%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.4ms